Facial palsy Revealing AR+/HER2+ Parotid carcinoma and the efficacy of HER2-Targeted therapy trastuzumab deruxtecan.

Salivary duct carcinomas present challenges to diagnosis and treatment due to diversity in histopathology and clinical behavior (Laurie & Licitra, 2006; Seethala, 2009). A 76-year-old male presented with gradual left-sided facial weakness that was discovered to be left parotid malignant salivary gland carcinoma. Treatment with fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody-drug conjugate, produced a favorable response. Results support an emerging "HER2-low" treatment protocol across diverse salivary gland malignancies.